INDP
NASDAQ · Biotechnology
Indaptus Therapeutics Inc
$3.29
-0.56 (-14.55%)
Open$3.78
Previous Close$3.85
Day High$3.83
Day Low$3.13
52W High$8.57
52W Low$0.92
Volume—
Avg Volume1.16M
Market Cap614.33M
P/E Ratio—
EPS$-7.75
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,139.2% upside
Current
$3.29
$3.29
Target
$40.77
$40.77
$30.54
$40.77 avg
$54.50
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.71M | 1.62M | 1.61M |
| Net Income | -161,760 | -172,924 | -142,728 |
| Profit Margin | -9.5% | -10.7% | -8.9% |
| EBITDA | -256,082 | -275,942 | -257,647 |
| Free Cash Flow | -132,527 | -99,336 | -105,630 |
| Rev Growth | +0.4% | +1.6% | -5.5% |
| Debt/Equity | 0.26 | 0.25 | 0.24 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |